StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > DECEMBER MEETING - CONTINGENT SHARE VOTE

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Oct 18, 2021 10:56am

141 Views

Post# 34017941

RE:DECEMBER MEETING - CONTINGENT SHARE VOTE

The UK clinic licence and overall milestones for achieving certain levels of revenue etc are 2 different things:

2,500,000 common shares, contingent upon Clinic Operations Limited obtaining a Care Quality Commission licence in the United Kingdom;

8,000,000 common shares contingent upon the achievement of certain milestones ("Milestones") and StageZero shareholder approval (the "Contingent Shares"). In the event the Milestones are achieved, and the StageZero shareholders do not approve of the issuance of the Contingent Shares, StageZero is obligated to pay to Health Clinics Limited, in lieu of the Contingent Shares, CAD $16,000,000, payable at a rate of 9.5% out of StageZero's monthly gross revenues. The Contingent Consideration becomes immediately payable in the event of a take-over bid.

Photoman77 wrote: The December meeting will not involve a RS option so you bashers can stop wetting your beds with excitement.

Care Oncology originally agreed to the deal with StageZero at a much higher price point, yet still proceeded to completed the deal at a huge discount due to sp drop. Many of the people associated with Care Oncology who are financially vested in the StageZero acquisition deal are now with StageZero so their putting a reverse share (rs) option on the table at this time in in their best interest. Plus was already taken off the table this summer.

The meeting in December is for approval of the completed milestone of UK license that requires shareholder approval to release the shares. --------

8,000,000 common shares contingent upon the achievement of certain milestones ("Milestones") and StageZero shareholder approval (the "Contingent Shares"). In the event the Milestones are achieved, and the StageZero shareholders do not approve of the issuance of the Contingent Shares, StageZero is obligated to pay to Health Clinics Limited, in lieu of the Contingent Shares, CAD $16,000,000, payable at a rate of 9.5% out of StageZero's monthly gross revenues. The Contingent Consideration becomes immediately payable in the event of a take-over bid.